A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Acute Myeloid Leukemia (AML)

Purpose

The purpose of this study is to assess how bleximenib and Venetoclax (VEN)+ Azacitidine (AZA) works as compared to placebo and VEN+AZA alone for the treatment of participants with Acute Myeloid Leukemia (AML) with a mutation in the NPM1 or KMT2A gene.

Condition

  • Leukemia, Myeloid, Acute

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Be 18 years of age or older at the time of informed consent - Previously untreated lysine N-methyltransferase 2A gene rearranged (KMT2Ar) or nucleophosmin 1 gene mutated (NPM1m) acute myeloid leukemia (AML) with greater than or equal to (> or =) 10% bone marrow blasts per 2022 international Consensus Classification criteria - Ineligible for intensive chemotherapy based on the following criteria: a) >= 75 years of age and ineligible per physician's discretion, with Eastern Cooperative Oncology Group (ECOG) performance status of 0-2, b) >=18 to <75 years of age with >= 1 of the following comorbidities: i) ECOG performance status of 2, ii) Severe cardiac disorder, iii) Severe pulmonary disorder, iv) Renal impairment, v) Comorbidity that, in the investigator's opinion, makes the participant unsuitable for intensive chemotherapy, which must be documented before enrollment as defined in the protocol. Ineligibility for intensive chemotherapy should be explicitly approved by a multidisciplinary team in countries in which this process is standard of care. - Participants must have adequate hepatic and renal function - A female participant must agree not to be pregnant, breast-feed, plan to become pregnant and use protocol-specified contraception while enrolled in this study and for 6 months after the last dose of study treatment - A male participant must agree to use protocol-specified contraception while enrolled in this study for at least 90 days after the last dose of study treatment - Must sign an informed consent form indicating that the participant understands the purpose of, and procedures required for, the study and is willing to participate in the study

Exclusion Criteria

  • Diagnosis of acute promyelocytic leukemia (APL) - Known active leukemic involvement of the central nervous system (CNS) - Recipient of solid organ transplant - Any cardiac disorders such as heart attack, uncontrolled/unstable chest pain, congestive heart failure, uncontrolled or symptomatic irregular heartbeat, blockage of a blood vessel to brain, or transient ischemic (decreased oxygen in tissue) attack within 6 months of randomization - Active infectious hepatitis - Live, attenuated vaccine within 4 weeks of randomization - Known allergies, hypersensitivity, or intolerance of bleximenib, azacitidine, or venetoclax excipients

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA) 		Participants with acute myeloid leukemia (AML) will receive bleximenib in combination with venetoclax (VEN) and azacitidine (AZA) for 28-days treatment cycles and treatment will continue until progression or unacceptable toxicity.
  • Drug: Bleximenib
    Bleximenib will be administered orally.
    Other names:
    • JNJ-75276617
  • Drug: Venetoclax (VEN)
    VEN will be administered orally.
  • Drug: Azacitidine (AZA)
    AZA will be administered intravenously or subcutaneously.
Placebo Comparator
Arm B: Placebo and Venetoclax (VEN) + Azacitidine (AZA) 		Participants with AML will receive placebo in combination with VEN and AZA for 28-days treatment cycles, and treatment will continue until progression or unacceptable toxicity.
  • Drug: Venetoclax (VEN)
    VEN will be administered orally.
  • Drug: Azacitidine (AZA)
    AZA will be administered intravenously or subcutaneously.
  • Drug: Placebo
    Placebo will be administered orally.

Recruiting Locations

University of Arkansas at Little Rock
Little Rock 4119403, Arkansas 4099753 72204

Orlando Health Cancer Institute
Orlando 4167147, Florida 4155751 32806

Moffit Cancer center
Tampa 4174757, Florida 4155751 33612

Cleveland Clinic Florida
Weston 4178003, Florida 4155751 33331

Norton Cancer Institute
Louisville 4299276, Kentucky 6254925 40207

Washington University in St Louis
St Louis 4407066, Missouri 4398678 63130

Roswell Park Comprehensive Cancer Center
Buffalo 5110629, New York 5128638 14263

Atrium Health
Charlotte 4460243, North Carolina 4482348 28204

Gabrail Cancer Center
Canton 5149222, Ohio 5165418 44718

University Hospitals Cleveland Medical Center
Cleveland 5150529, Ohio 5165418 44106

Cleveland Clinic
Cleveland 5150529, Ohio 5165418 44195

Providence Portland Medical Center
Portland 5746545, Oregon 5744337 97213

Providence Oncology and Hematology Care Clinic Westside
Portland 5746545, Oregon 5744337 97225

Thomas Jefferson University
Philadelphia 4560349, Pennsylvania 6254927 19107

University of Tennessee
Knoxville 4634946, Tennessee 4662168 37920

Baylor University Medical Center
Dallas 4684888, Texas 4736286 75246

MD Anderson Cancer Center
Houston 4699066, Texas 4736286 77030

Swedish Cancer Institute
Seattle 5809844, Washington 5815135 98104

More Details

NCT ID
NCT06852222
Status
Recruiting
Sponsor
Janssen Research & Development, LLC

Study Contact

Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com